目的：探讨Nanog 和CD44蛋白在肺癌中的表达及其临床意义。方法：采用免疫组化检测50例肺癌组织、32例良性病变肺组织和18例癌旁正常肺组织中Nanog和CD44蛋白的表达，并分析二者与肺癌临床病理因素的关系。结果：Nanog 在肺癌中的表达显著高于良性病变肺组织和正常肺组织（P＜0．05）；CD44在肺癌、良性病变肺组织和正常肺组织中的表达无统计学差异（P＞0．05）；Nanog 和CD44在肺鳞癌中的表达显著高于肺腺癌和小细胞肺癌（P＜0．05）；Nanog 和CD44在肺癌中的表达与淋巴结转移相关（P＜0．05），与肺癌患者的性别、年龄、肿瘤大小、TNM分期和肿瘤分化无关（P＞0．05）。 Nanog 和CD44在肺癌中的表达呈正相关（r＝0．564，P＜0．05）。结论：Nanog和CD44蛋白可能共同参与了肺癌的发生发展，Nanog蛋白是一潜在的肺癌诊断标志物及治疗靶点。%Objective To detect the expressions and clinical significance of Nanog and CD44 protein in lung cancer. Methods The expressions of Nanog and CD44 were detected by immunohistochemistry in 50 cases of lung cancer, 32 cases of benign lesion lung tissue and 18 cases of paraneoplastic normal lung tissue. Then their relationships with clinicopathological factors were analyzed. Results The expression of Nanog in lung cancer was significantly higher than those in benign lesion lung tissue and paraneoplastic normal lung tissue (P < 0.05). There was no significant difference of the expression of CD44 among the three groups (P > 0.05). The expressions of Nanog and CD44 in squamous cell carcinomas were higher than those in adenocarcinomas and small cell lung carcinomas (P < 0.05). The expressions of Nanog and CD44 were significantly correlated with lymph node metastasis (P < 0.05), but were not correlated with age, gender, tumour size, TNM stage and differentiation of lung cancer (P>0.05). The positive correlation was also noted between the expressions of Nanog and CD44 in lung cancer (r = 0.564, P < 0.05). Conclusion Nanog and CD44 proteins may participate in the genesis and progression of lung cancer. Nanog protein is a potential diagnostic marker and therapeutic target for lung cancer.
展开▼
